|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
65,769,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nuvalent is a biopharmaceutical company. Co.'s product candidate, NVL-520, is a ROS proto-oncogene 1 (ROS1)-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of available ROS1 tyrosine kinase inhibitors. Co.'s another product candidate, NVL-655, is a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor, designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-, second-, and third-generation ALK inhibitors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
799,253 |
Total Buy Value |
$0 |
$0 |
$0 |
$26,774,976 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
1,132,833 |
1,374,179 |
1,588,071 |
1,862,739 |
Total Sell Value |
$82,196,365 |
$100,295,974 |
$110,820,634 |
$118,384,513 |
Total People Sold |
5 |
7 |
8 |
8 |
Total Sell Transactions |
12 |
21 |
47 |
78 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shair Matthew |
|
|
2024-04-22 |
4 |
AS |
$62.66 |
$2,386,910 |
D/D |
(37,500) |
1,537,198 |
|
- |
|
Shair Matthew |
|
|
2024-04-15 |
4 |
AS |
$65.27 |
$2,458,335 |
D/D |
(37,500) |
1,574,698 |
|
- |
|
Conley Emily |
|
|
2024-04-15 |
4 |
AS |
$65.52 |
$327,607 |
D/D |
(5,000) |
8 |
|
- |
|
Conley Emily |
|
|
2024-04-15 |
4 |
OE |
$9.36 |
$46,800 |
D/D |
5,000 |
5,008 |
|
- |
|
Shair Matthew |
|
|
2024-04-08 |
4 |
AS |
$67.89 |
$2,566,479 |
D/D |
(37,500) |
1,612,198 |
|
- |
|
Miller Deborah Ann |
Chief Legal Officer |
|
2024-04-04 |
4 |
AS |
$71.54 |
$220,787 |
D/D |
(3,000) |
33,300 |
|
- |
|
Miller Deborah Ann |
Chief Legal Officer |
|
2024-04-04 |
4 |
OE |
$6.89 |
$20,670 |
D/D |
3,000 |
36,300 |
|
- |
|
Shair Matthew |
|
|
2024-04-01 |
4 |
AS |
$76.82 |
$2,884,337 |
D/D |
(37,500) |
1,649,698 |
|
- |
|
Miller Deborah Ann |
Chief Legal Officer |
|
2024-03-28 |
4 |
AS |
$74.23 |
$1,654,311 |
D/D |
(22,000) |
33,300 |
|
- |
|
Miller Deborah Ann |
Chief Legal Officer |
|
2024-03-28 |
4 |
OE |
$18.93 |
$496,740 |
D/D |
22,000 |
55,300 |
|
- |
|
Hack Andrew A. F. |
|
|
2024-03-27 |
4 |
S |
$72.31 |
$64,035,959 |
I/I |
(880,000) |
2,697,267 |
|
- |
|
Shair Matthew |
|
|
2024-03-25 |
4 |
AS |
$76.74 |
$153,546 |
I/I |
(2,000) |
238,522 |
|
- |
|
Shair Matthew |
|
|
2024-03-25 |
4 |
AS |
$76.74 |
$2,878,982 |
D/D |
(37,500) |
1,687,198 |
|
- |
|
Noci Darlene |
Chief Development Officer |
|
2024-03-22 |
4 |
AS |
$77.25 |
$1,550,229 |
D/D |
(20,000) |
33,300 |
|
- |
|
Noci Darlene |
Chief Development Officer |
|
2024-03-22 |
4 |
OE |
$1.08 |
$154,800 |
D/D |
20,000 |
53,300 |
|
- |
|
Conley Emily |
|
|
2024-03-15 |
4 |
AS |
$79.81 |
$1,078,883 |
D/D |
(13,333) |
8 |
|
- |
|
Conley Emily |
|
|
2024-03-15 |
4 |
OE |
$9.36 |
$124,797 |
D/D |
13,333 |
13,341 |
|
- |
|
Turner Christopher Durant |
Chief Medical Officer |
|
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,300 |
47,813 |
|
- |
|
Porter James Richard |
President and CEO |
|
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
112,800 |
188,113 |
|
- |
|
Balcom Alexandra |
Chief Financial Officer |
|
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,300 |
33,300 |
|
- |
|
Noci Darlene |
Chief Development Officer |
|
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,300 |
33,300 |
|
- |
|
Miller Deborah Ann |
Chief Legal Officer |
|
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,300 |
33,300 |
|
- |
|
Shair Matthew |
Director |
|
2023-12-28 |
4 |
AS |
$75.20 |
$3,663,492 |
D/D |
(48,548) |
1,724,698 |
|
- |
|
Shair Matthew |
Director |
|
2023-12-27 |
4 |
AS |
$75.17 |
$75,170 |
D/D |
(1,000) |
1,773,246 |
|
- |
|
Shair Matthew |
Director |
|
2023-12-26 |
4 |
AS |
$74.22 |
$5,228,346 |
D/D |
(69,602) |
1,774,246 |
|
- |
|
150 Records found
|
|
Page 1 of 6 |
|
|